Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix

Syed, A.M. Nisar; Puthawala, Ajmel; Abdelaziz, Nashwa Nazmy; El-Naggar, M.; DiSaia, Philip J.; Berman, Michael L.; Tewari, Krishnansu S.; Sharma, Anil Kumar; Londrc, Adina; Juwadi, Supriya; Cherlow, Joel M.; Damore, Steven J; Chen, Yi Jen

doi:10.1016/s0360-3016(02)02900-0

Cited by 94 publications

(38 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interstitial brachytherapy with transperineal approach in locally advanced cervical cancer is a well-established method for decades and there are numerous studies on ISBT; the vast majority of them are from 2D era [25, 26, 27, 28]. However, there is also an increasing number of studies based on 3D image-based brachytherapy [19, 20, 29, 30, 31].…”

Section: Discussionmentioning

confidence: 99%

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

Murakami¹,

Kobayashi²,

Kato

et al. 2016

jcb

View full text Add to dashboard Cite

PurposeThe aim of this study was to report the clinical results of uterine cervical cancer patients treated by primary radiation therapy including brachytherapy, and investigate the role of interstitial brachytherapy (ISBT).Material and methodsAll consecutive uterine cervical cancer patients who were treated by primary radiation therapy were reviewed, and those who were treated by ISBT were further investigated for clinical outcomes and related toxicities.ResultsFrom December 2008 to October 2014, 209 consecutive uterine cervical cancer patients were treated with primary radiation therapy. Among them, 142 and 42 patients were treated by intracavitary and hybrid brachytherapy, respectively. Twenty-five patients (12%) were treated by high-dose-rate (HDR)-ISBT. Five patients with distant metastasis other than para-aortic lymph node were excluded, and 20 patients consisted of the analysis. Three-year overall survival (OS), progression-free survival (PFS), and local control (LC) rate were 44.4%, 38.9%, and 87.8%, respectively. Distant metastasis was the most frequent site of first relapse after HDR-ISBT. One and four patients experienced grade 3 and 2 rectal bleeding, one grade 2 cystitis, and two grade 2 vaginal ulcer.ConclusionsFeasibility and favorable local control of interstitial brachytherapy for locally advanced cervical cancer was demonstrated through a single institutional experience with a small number of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

Murakami¹,

Kobayashi²,

Kato

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…Stage III patients had a 5-year diseasefree survival of 49%; Stage IIIB patients had a locoregional control rate of 61%. 49 For interstitial implantation with HDR, Demanes et al treated 62 patients with six fractions of HDR over two insertions; with a mean follow-up of 40 months, the 5-year disease-free survival rate for Stage III patients was 39%, but the regional pelvic control rate was 79%. 50 A report of a combined tandem and ring with interstitial applicator using HDR on a fractionated basis was published, though longterm survival and toxicity data are not yet available.…”

Section: Interstitial Implantationmentioning

confidence: 99%

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago. However, certain aspects of the use of high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy. This study represents a systematic literature review of prospective and retrospective series of patients with cervical carcinoma treated with external-beam radiation

show abstract

“…Because treatment applicators can be implanted in and/or around the CTV, ISBT has the possibility to achieve better tumor coverage regardless of the size of the vaginal and uterine cavity in cases of cervical cancer. The ABS recommends that ISBT should be used in situations such as bulky lesion, narrow vagina, inability to enter the cervical os, extension to the lateral parametrium or pelvic side wall, and lower vaginal extension (5), and several clinical reports have shown good local control results using low-dose-rate or highdose-rate (HDR) ISBT (6)(7)(8)(9)(10)(11)(12). Based on these recommendations, we performed ISBT with metal applicators until May 2005.…”

Section: Introductionmentioning

confidence: 99%

A Dose–Volume Analysis of Magnetic Resonance Imaging-Aided High-Dose-Rate Image-Based Interstitial Brachytherapy for Uterine Cervical Cancer

Yoshida¹,

Yamazaki²,

Takenaka³

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix

Cited by 94 publications

References 58 publications

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

A Dose–Volume Analysis of Magnetic Resonance Imaging-Aided High-Dose-Rate Image-Based Interstitial Brachytherapy for Uterine Cervical Cancer

Contact Info

Product

Resources

About